EA200702271A1 - Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в - Google Patents

Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в

Info

Publication number
EA200702271A1
EA200702271A1 EA200702271A EA200702271A EA200702271A1 EA 200702271 A1 EA200702271 A1 EA 200702271A1 EA 200702271 A EA200702271 A EA 200702271A EA 200702271 A EA200702271 A EA 200702271A EA 200702271 A1 EA200702271 A1 EA 200702271A1
Authority
EA
Eurasian Patent Office
Prior art keywords
apo
secretion
compounds
triglicerides
transport inhibitors
Prior art date
Application number
EA200702271A
Other languages
English (en)
Other versions
EA024768B1 (ru
Inventor
Алессандра Бартолоци
А. Кэмпбелл
Хопе Фадалакис
Инох Ким
Пол Свитнэм
Йингфей Йанг
Original Assignee
Сюрфэйс Лоджикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сюрфэйс Лоджикс, Инк. filed Critical Сюрфэйс Лоджикс, Инк.
Publication of EA200702271A1 publication Critical patent/EA200702271A1/ru
Publication of EA024768B1 publication Critical patent/EA024768B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям, которые являются ингибиторами белка микросомального транспорта триглицеридов и/или секреции аполипопротеида В (Апо-В). Эти соединения могут быть применимы для профилактики и лечения различных заболеваний, в частности атеросклероза и его клинических осложнений, для снижения содержания липидов в сыворотке и ассоциированных заболеваний. Изобретение дополнительно относится к содержащим соединения фармацевтическим композициям и способам лечения таких заболеваний, как гипертриглицеридемия, гиперхиломикронемия, атеросклероз, ожирение и ассоциированные состояния, с использованием соединений. Также раскрыт способ ослабления секреции аполипопротеида В (апо-В).
EA200702271A 2005-04-19 2006-04-19 Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в EA024768B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67277805P 2005-04-19 2005-04-19
US75539005P 2005-12-30 2005-12-30
PCT/US2006/015146 WO2006113910A2 (en) 2005-04-19 2006-04-19 Inhibitors of microsomal triglyceride transfer protein and apo-b secretion

Publications (2)

Publication Number Publication Date
EA200702271A1 true EA200702271A1 (ru) 2008-04-28
EA024768B1 EA024768B1 (ru) 2016-10-31

Family

ID=37115969

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702271A EA024768B1 (ru) 2005-04-19 2006-04-19 Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в

Country Status (19)

Country Link
US (2) US8980915B2 (ru)
EP (1) EP1877369B1 (ru)
JP (1) JP5356017B2 (ru)
KR (1) KR20080015792A (ru)
AU (1) AU2006236226B2 (ru)
BR (1) BRPI0607555A2 (ru)
CA (1) CA2605510C (ru)
CR (1) CR9528A (ru)
EA (1) EA024768B1 (ru)
EC (1) ECSP077913A (ru)
ES (1) ES2430319T3 (ru)
GE (1) GEP20104878B (ru)
IL (1) IL186820A0 (ru)
MX (1) MX2007013133A (ru)
NI (1) NI200700272A (ru)
NO (1) NO20075731L (ru)
NZ (1) NZ563009A (ru)
SG (1) SG164371A1 (ru)
WO (1) WO2006113910A2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607555A2 (pt) 2005-04-19 2009-09-15 Surface Logix Inc inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
NZ571569A (en) 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009043353A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE124408T1 (de) * 1990-10-16 1995-07-15 Takeda Chemical Industries Ltd Heterozyklische aminderivate, deren herstellung und deren verwendung.
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
MX9709914A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
EP1181954A3 (en) * 1995-06-07 2002-08-21 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion
NZ330216A (en) 1996-01-16 2000-09-29 Bristol Myers Squibb Co Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
DE60110896T2 (de) 2000-01-18 2006-01-12 Novartis Ag Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US20050038035A1 (en) * 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
JP2003231633A (ja) 2002-02-06 2003-08-19 Tanabe Seiyaku Co Ltd 医薬組成物
OA13365A (en) * 2004-02-04 2007-04-13 Pfizer Prod Inc Substituted quinoline compounds.
BRPI0607555A2 (pt) 2005-04-19 2009-09-15 Surface Logix Inc inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b

Also Published As

Publication number Publication date
EP1877369B1 (en) 2013-07-10
BRPI0607555A2 (pt) 2009-09-15
CA2605510A1 (en) 2006-10-26
NO20075731L (no) 2008-01-17
CR9528A (es) 2008-05-21
JP2008538568A (ja) 2008-10-30
ECSP077913A (es) 2008-01-23
US8980915B2 (en) 2015-03-17
AU2006236226B2 (en) 2012-07-05
EA024768B1 (ru) 2016-10-31
JP5356017B2 (ja) 2013-12-04
US20070027183A1 (en) 2007-02-01
NI200700272A (es) 2008-07-11
SG164371A1 (en) 2010-09-29
ES2430319T3 (es) 2013-11-20
IL186820A0 (en) 2008-02-09
WO2006113910A3 (en) 2007-03-22
WO2006113910A2 (en) 2006-10-26
CA2605510C (en) 2013-12-24
AU2006236226A1 (en) 2006-10-26
KR20080015792A (ko) 2008-02-20
EP1877369A4 (en) 2010-04-14
EP1877369A2 (en) 2008-01-16
NZ563009A (en) 2011-05-27
US20160039765A1 (en) 2016-02-11
GEP20104878B (en) 2010-01-11
MX2007013133A (es) 2008-03-14
US9656960B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
EA200702271A1 (ru) Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
ATE460164T1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
DK1365762T3 (da) Fremgangsmåde til forögelse af leptinniveauer under anvendelse af nicotinsyreforbindelser
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE405840T1 (de) Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA200702674A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EA201170670A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
WO2010065077A3 (en) Antagonists of il-6 to prevent or treat thrombosis
EA200900298A1 (ru) Ингибиторы вируса гепатита с
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
EA200801008A1 (ru) Гипохолестеринемические соединения
EA200870089A1 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
DE602006020775D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
EA200600588A1 (ru) Соединения, содержащие галоидалкил, как ингибиторы цистеиновых протеаз
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201201550A1 (ru) Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU